Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Abstract

Background:

Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies directed against interferon β that interfere with treatment efficacy. Several observational studies have proposed different HLA alleles and genetic variants associated with the development of antibodies against interferon β.

Objective:

To validate the proposed genetic markers and to identify new markers.

Methods:

Associations of genetic candidate markers with antibody presence and development were examined in a post hoc analysis in 941 patients treated with interferon β-1b in the Betaferon^® Efficacy Yielding Outcomes of a New Dose (BEYOND) and BEtaseron^®/BEtaferon^® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) prospective phase III trials. All patients were treated with interferon β-1b for at least 6 months. In addition, a genome-wide association study was conducted to identify new genetic variants.

Results:

We confirmed an increased risk for carriers of HLA-DRB1*04:01 (odds ratio (OR) = 3.3, p = 6.9 × 10⁻⁴) and HLA-DRB1*07:01 (OR = 1.8, p = 3.5 × 10⁻³) for developing neutralizing antibodies (NAbs). Several additional, previously proposed HLA alleles and genetic variants showed nominally significant associations. In the exploratory analysis, variants in the HLA region were associated with NAb development at genome-wide significance (OR = 2.6, p = 2.30 × 10⁻¹⁵).

Conclusion:

The contribution of HLA alleles and HLA-associated single-nucleotide polymorphisms (SNPs) to the development and titer of antibodies against interferon β was confirmed in the combined analysis of two multi-national, multi-center studies.

Keywords

Multiple sclerosis interferon beta anti-drug antibodies genetic variation HLA-DRB1 genome-wide association study

Get full access to this article

View all access options for this article.

References

Van Schouwenburg

Rispens

Wolbink

GJ.

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 164–172.

Jawa

Cousens

Awwad

et al . T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol 2013; 149: 534–555.

Wroblewska

Reipert

Pratt

et al . Dangerous liaisons: How the immune system deals with factor VIII. J Thromb Haemost 2013; 11: 47–55.

Sørensen

Ross

Clemmesen

et al . Antibodies to IFN-beta: The Danish national IFN-beta project. Neurology 2013; 61: S27–S28.

Polman

Bertolotto

Deisenhammer

et al . Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740–750.

Bertolotto

Deisenhammer

Gallo

et al . Immunogenicity of interferon beta: Differences among products. J Neurol 2004; 251(Suppl. 2): II15–II24.

Deisenhammer

Interferon-beta: Neutralizing antibodies, binding antibodies, pharmacokinetics and pharmacodynamics, and clinical outcomes. J Interferon Cytokine Res 2014; 34: 938–945.

Sørensen

Ross

Clemmesen

et al . Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184–1191.

Bertolotto

Gilli

Sala

et al . Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60: 634–639.

10.

Kappos

Clanet

Sandberg-Wollheim

et al . Neutralizing antibodies and efficacy of interferon beta-1a: A 4-year controlled study. Neurology 2005; 65: 40–47.

11.

Pachner

Cadavid

Wolansky

et al . Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 2009; 73: 1485–1492.

12.

Torosantucci

Sharov

van Beers

et al . Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: Potential implications for protein aggregation and immunogenicity. Mol Pharm 2013; 10: 2311–2322.

13.

Barnard

Babcock

Carpenter

JF.

Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity. J Pharm Sci 2013; 102: 915–928.

14.

Bozhinov

Handzhiyski

Genov

et al . Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals. J Allergy Clin Immunol 2012; 129: 855–858.

15.

Buck

Cepok

Hoffmann

et al . Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011; 68: 480–487.

16.

Hoffmann

Cepok

Grummel

et al . HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008; 83: 219–227.

17.

Barbosa

MDFS

Vielmetter

Chu

et al . Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 2006; 118: 42–50.

18.

Núñez

Cénit

Alvarez-Lafuente

et al . HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis. J Med Genet 2014; 51: 395–400.

19.

Link

Ryner

Fink

et al . Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. PLoS ONE 2014; 9: e90479.

20.

Weber

Cepok

Wolf

et al . Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients. Pharmacogenomics J 2012; 12: 238–245.

21.

Kappos

Polman

Freedman

et al . Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–1249.

22.

O’Connor

Filippi

Arnason

et al . 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol 2009; 8: 889–897.

23.

Poser

Paty

Scheinberg

et al . New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

24.

Goodin

Hartung

H-P

O’Connor

et al . Neutralizing antibodies to interferon beta-1b multiple sclerosis: A clinico-radiographic paradox in the BEYOND trial. Mult Scler 2012; 18: 181–195.

25.

Hartung

Freedman

Polman

et al . Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 2011; 77: 835–843.

26.

Kappos

Freedman

Polman

et al . Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987–997.

27.

Sorensen

Deisenhammer

Duda

et al . Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: Report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817–827.

28.

Pungor

Files

Gabe

et al . A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998; 18: 1025–1030.

29.

Price

Patterson

Plenge

et al . Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904–909.

30.

Howie

Donnelly

Marchini

A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.

31.

Howie

Fuchsberger

Stephens

et al . Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955–959.

32.

Delaneau

Zagury

J-F

Marchini

Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods 2013; 10: 5–6.

33.

Therneau

Grambsch

PM.

Modeling survival data: Extending the cox model. Berlin: Springer, 2010.

34.

Chang

Chow

Tellier

et al . Second-generation PLINK: Rising to the challenge of larger and richer datasets. Gigascience 2015; 4: 7.

35.

Melé

Ferreira

Reverter

et al . Human genomics: The human transcriptome across tissues and individuals. Science 2015; 348: 660–665.

36.

Lin

P-I

Vance

Pericak-Vance

et al . No gene is an island: The flip-flop phenomenon. Am J Hum Genet 2007; 80: 531–538.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.88 MB